Ashley Black, DO
Pulmonary Disease · Chicago, ILNPI 1316254139
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.7%), consulting fees and education — rather than concentrated in one kind of arrangement. Sanofi accounts for 63.5% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $28,510, more than ten times the $1,146 reported in 2019. Among pulmonary disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $194.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$29K
- Intuitive Surgical$12K
- GSK$1K
- Verathon Inc.$1K
- Inari Medical, Inc.$390
- Boehringer Ingelheim$293
- plus $2K from 27 others
What the payments were for
- Consulting fees$10,59523%
- Speaking & faculty fees$18,13640%
- Travel & lodging$2,0234%
- Food & beverage$5,71613%
- Education$9,24320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 36 | $29,045 |
| Intuitive Surgical | 17 | $11,645 |
| GSK | 97 | $1,354 |
| Verathon Inc. | 1 | $1,000 |
| Inari Medical, Inc. | 2 | $390 |
| Boehringer Ingelheim | 8 | $293 |
| AstraZeneca | 9 | $282 |
| Mallinckrodt Enterprises LLC | 6 | $224 |
| Regeneron Healthcare Solutions, Inc. | 7 | $205 |
| Actelion Pharmaceuticals US, Inc. | 2 | $117 |
| Abiomed | 1 | $109 |
| Electromed, Inc. | 15 | $105 |
| Livanova USA, Inc. | 1 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Insmed, Inc. | 4 | $87 |
| Philips North America LLC | 3 | $83 |
| Merck | 3 | $66 |
| Genentech USA, Inc. | 2 | $64 |
| Mylan Specialty L.p. | 3 | $60 |
| Circassia Inc. | 1 | $48 |
| Siemens Medical Solutions USA, Inc. | 2 | $42 |
| Inogen, Inc. | 1 | $40 |
| Shionogi Inc | 2 | $33 |
| Amgen | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Ambu Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $23 |
| Chiesi USA, Inc. | 1 | $18 |
| Pulmonx Corporation | 1 | $17 |
| AbbVie | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$26,401
- ION$9,000
- Da Vinci Surgical System$1,369
- DA VINCI SP$1,000
- Bronoscope$1,000
- FLOWTRIEVER CATHETER, S$390
- CT THROMBECTOMY SYSTEM KIT$390
- SYMBICORT$124
- FASENRA$124
- ACTHAR$118
- TRELEGY ELLIPTA$114
- Impella$109
- LifeSPARC$104
How this compares
$45,713 in reported general payments places this provider in the 90th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 199 | $178,807 |
| Dupixent PenDupilumab | 28 | $121,290 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 146 | $78,878 |
| Breo ElliptaFluticasone/Vilanterol | 118 | $57,294 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $27,942 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 37 | $19,267 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $12,451 |
| Spiriva RespimatTiotropium Bromide | 18 | $11,405 |
| EliquisApixaban | 15 | $9,151 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $6,282 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 12 | $5,670 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $4,988 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $4,406 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $3,104 |
| Ventolin HfaAlbuterol Sulfate | 18 | $1,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,354 | $321,261482 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $282 | $59,661110 claims |
| Boehringer IngelheimSpiriva Respimat | $293 | $11,40518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Chicago
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Manu JainChicago$187K
- Richard WunderinkChicago$178K
- Rade TomicChicago$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.